Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Century Therapeutics, Inc.NASDAQ: IPSC

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $3M fell 6.7% year over year, behind the -3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 15.4% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Depreciation & amortization amounted to 12.0% of revenue in FY2025, down 189.9 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -3.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3M-15.4% QoQ
Last fiscal yearDec 2025
$13.1M-1.5% YoY
LTMMar 2026
$12.88M-3.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.7%——
1 year-1.5%——
3-year CAGR+15.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
13.1M USD
Year-over-year change
-1.5%
4-year CAGR
+36.7%

Depreciation & Amortization vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 depreciation & amortization of $12.88M is the 2nd largest of the 8 companies compared; the peer median is $1.23M.
  • Its year-over-year change of -3.1% is the 5th highest of 7, against a peer median of +8.0%.
  • Over three fiscal years its annual growth of +15.8% compares with a peer median of -0.6%.
IPSC Competitors Peer median
Depreciation & Amortization for IPSC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$363.33M +106428.1%+7569.0%—
IPSCCentury Therapeutics, Inc.LTM Mar 2026$12.88M -3.1%+15.8%—
CUECue Biopharma, Inc.LTM Mar 2026$2.9M +21.7%-19.1%8.9%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$2.56M -49.9%—1.7%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +12.3%+6.9%86.8%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$119.64K +3.7%-17.0%35.9%
EQEquillium, Inc.LTM Mar 2026$107K -22.5%-0.6%—
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding IPSC) $1.23M+8.0%-0.6%22.4%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Depreciation & Amortization3.75M8.44M13.04M13.3M13.1M
Deferred Income Tax000870K(73K)
Stock-Based Compensation4.66M10.67M14.62M12.69M6.84M
Change in Working Capital(2.8M)123.95M9.38M(9.28M)(114.55M)
Accounts Receivables00000
Inventory00000
Accounts Payables(1.85M)(4.79M)(2.36M)(1.47M)1.56M
Other Working Capital(949K)128.73M11.74M(7.81M)(116.12M)
Other Non-Cash Items1.21M1.93M11.28M(1.15M)389K
Operating Cash Flow(89M)14.05M(88.35M)(110.14M)(103.88M)
Capital Expenditures(44.97M)(30.6M)(13.74M)(154K)(848K)
Acquisitions (Net)0(238.22M)0(9.61M)0
Purchases of Investments(330.03M)(254M)(209.03M)(119.55M)(51.17M)
Sales of Investments76.67M271.48M283.9M176.79M(51.17M)
Other Investing Activities0238.22M00210.7M
Investing Cash Flow(298.34M)(13.13M)61.13M47.48M107.5M
Debt Repayment00(10.24M)00
Common Stock Issued221.62M27.16M516K74.56M173K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities36.53M0000
Financing Cash Flow417.77M27.16M(9.73M)74.56M173K
Effect of Forex Changes00000
Net Change in Cash30.43M28.08M(36.94M)11.91M3.8M
Free Cash Flow(133.97M)(16.55M)(102.08M)(110.29M)(104.72M)

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.